When does the Stelara (ustekinumab) patent expire?
Patent-expiration timelines for Stelara depend on which specific U.S. (and sometimes international) patents and exclusivities you’re looking at. In practice, companies and markets track multiple layers of protection, including patents on the active biologic, process patents, formulation patents, and additional exclusivity mechanisms.
You can check the latest, case-specific patent dates for Stelara on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/stelara/ 1
How long is the exclusivity (not just patents) for Stelara?
Even after a patent term ends, additional regulatory exclusivities or other protected claims can delay a competitor’s ability to launch a generic or biosimilar version. For biologics like Stelara (ustekinumab), biosimilar pathways typically hinge on both patent status and FDA exclusivity/patent litigation history.
For an up-to-date mapping of relevant protections and dates, see the Stelara entry on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/stelara/ 1
Which protections matter most for biosimilar entry to Stelara?
For Stelara, the ability of a biosimilar applicant to launch can be affected by:
- Which patents are still in force (and where)
- Whether key patents are found infringed (or not) during litigation
- Whether additional exclusivity extends beyond the base patent term
DrugPatentWatch.com typically aggregates these into an easier-to-check timeline by patent family and status for Stelara: https://www.drugpatentwatch.com/p/stelara/ 1
Want the exact date for the U.S. “last” patent expiration?
If you tell me the geography you care about (U.S., EU, UK, etc.) and whether you want “latest patent expiration” or “earliest biosimilar launch possible,” I can help you interpret what the Stelara patent table on DrugPatentWatch.com is showing for your use case. The key starting point is the Stelara patent listing: https://www.drugpatentwatch.com/p/stelara/ 1
Sources